Stock Scorecard



Stock Summary for Johnson & Johnson (JNJ) - $163.71 as of 3/28/2025 8:14:10 PM EST

Total Score

10 out of 30

Safety Score

69 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for JNJ

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for JNJ

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for JNJ

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for JNJ

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for JNJ (69 out of 100)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 7
Book Value (Max of 10) 7
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 6
Operating Margin (Max of 10) 4
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 6
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for JNJ

Excitement Builds for Tremfya Among US Gastroenterologists as the FDA Approves its Expansion into Crohn's Disease, Suggesting the Brand May Impact Competitor Skyrizi's Growth 3/28/2025 5:58:00 PM
Vicon's new markerless system enabling Dreamscape Immersive's latest VR experience 3/28/2025 11:57:00 AM
LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update 3/28/2025 11:30:00 AM
Investors Are Flocking to These 3 Vanguard Sector ETFs. Should You Buy Them Too? 3/28/2025 9:42:00 AM
Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 ( JNJ-1900 ) as a 2L+ Therapy for Patients With Locally Advanced NSCLC 3/27/2025 8:15:00 PM
International Expansion, Product Launches Support BSX Stock 3/27/2025 4:01:00 PM
Investors Heavily Search Johnson & Johnson ( JNJ ) : Here is What You Need to Know 3/27/2025 1:00:00 PM
2 Recession-Proof Dividend Stocks to Buy and Hold 3/27/2025 9:25:00 AM
Alvotech Reports Record Results for 2024 and Provides Business Update 3/26/2025 10:36:00 PM
Alvotech Reports Record Results for 2024 and Provides Business Update 3/26/2025 10:34:00 PM

Financial Details for JNJ

Company Overview

Ticker JNJ
Company Name Johnson & Johnson
Country USA
Description Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date 4/14/2025

Stock Price History

Last Day Price 163.71
Price 4 Years Ago 155.60
Last Day Price Updated 3/28/2025 8:14:10 PM EST
Last Day Volume 5,750,453
Average Daily Volume 9,080,320
52-Week High 169.99
52-Week Low 138.68
Last Price to 52 Week Low 18.05%

Valuation Measures

Trailing PE 27.93
Industry PE 37.01
Sector PE 40.10
5-Year Average PE 15.66
Free Cash Flow Ratio 15.80
Industry Free Cash Flow Ratio 11.91
Sector Free Cash Flow Ratio 47.05
Current Ratio Most Recent Quarter 1.11
Total Cash Per Share 10.36
Book Value Per Share Most Recent Quarter 29.70
Price to Book Ratio 5.43
Industry Price to Book Ratio 8.86
Sector Price to Book Ratio 21.92
Price to Sales Ratio Twelve Trailing Months 4.39
Industry Price to Sales Ratio Twelve Trailing Months 88.85
Sector Price to Sales Ratio Twelve Trailing Months 27.78
Analyst Buy Ratings 7
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 2,409,850,000
Market Capitalization 394,516,543,500
Institutional Ownership N/A

Dividends

Ex-Dividend Date 2/18/2025
Previous Dividend Amount 1.2400
Current Dividend Amount 1.2400
Total Years Dividend Increasing Dividend Aristocrat - Increasing for 42 Years
Trailing Annual Dividend Rate 4.96
Trailing Annual Dividend Yield 3.04%
Forward Annual Dividend Rate 4.96
Forward Annual Dividend Yield 3.04%
5-Year Dividend Payments Count 20
3-Year Average Dividend Yield 3.42%
5-Year Average Dividend Yield 2.98%
1-Year Dividend Growth Rate Percentage 1.02%
3-Year Dividend Growth Rate Percentage 0.51%
5-Year Dividend Growth Rate Percentage 4.31%
All-Time Dividend Growth Rate Percentage 13.03%
Dividend Payout Ratio 85.52%

Income Statement

Quarterly Earnings Growth YOY -3.40%
Annual Earnings Growth -59.99%
Reported EPS 12 Trailing Months 5.79
Reported EPS Past Year 9.99
Reported EPS Prior Year 10.43
Net Income Twelve Trailing Months 14,066,000,000
Net Income Past Year 14,066,000,000
Net Income Prior Year 35,153,000,000
Quarterly Revenue Growth YOY 5.30%
5-Year Revenue Growth 1.69%
Operating Margin Twelve Trailing Months 18.10%

Balance Sheet

Total Cash Most Recent Quarter 24,973,000,000
Total Cash Past Year 24,973,000,000
Total Cash Prior Year 27,400,000,000
Net Cash Position Most Recent Quarter -7,427,000,000
Net Cash Position Past Year -7,427,000,000
Long Term Debt Past Year 32,400,000,000
Long Term Debt Prior Year 27,350,000,000
Total Debt Most Recent Quarter 32,400,000,000
Equity to Debt Ratio Past Year 0.69
Equity to Debt Ratio Most Recent Quarter 0.69
Total Stockholder Equity Past Year 71,490,000,000
Total Stockholder Equity Prior Year 68,774,000,000
Total Stockholder Equity Most Recent Quarter 71,490,000,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 19,842,000,000
Free Cash Flow Per Share Twelve Trailing Months 8.23
Free Cash Flow Past Year 19,842,000,000
Free Cash Flow Prior Year 18,248,000,000

Options

Put/Call Ratio 1.09
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 1.18
MACD Signal 1.83
20-Day Bollinger Lower Band 136.32
20-Day Bollinger Middle Band 152.81
20-Day Bollinger Upper Band 169.31
Beta 0.46
RSI 55.92
50-Day SMA 152.20
150-Day SMA 153.79
200-Day SMA 153.65

System

Modified 3/28/2025 12:02:26 AM EST